Agoracom Blog Home

Posts Tagged ‘Hemp’

« Older Entries
Newer Entries »

Tetra Bio-Pharma $TBP.ca Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:21 AM on Tuesday, November 13th, 2018

Logo tetrabiopharma rgb web

  • Announced the promotion of Steeve Néron as Senior Vice President, Marketing and Medical Affairs. The Corporation also announced the conclusion of the dividend-in-kind of North Bud Farms
  • Mr. Néron will be responsible for prioritizing development of commercialization opportunities and market potential for both Tetra Bio-Pharma and Tetra Natural Health products. He will be overseeing all pre-launch activities such as Continuing Medical Education (CME), Medical Science Liaison (MSL) and Market Access/Reimbursement. 
  • Tetra Also Clarifies Estimated Fair Market Value of North Bud Farms Shares

ORLEANS, Ontario, Nov. 13, 2018 — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce the promotion of Steeve Néron as Senior Vice President, Marketing and Medical Affairs. The Corporation also announced the conclusion of the dividend-in-kind of North Bud Farms Inc.

Mr. Néron will be responsible for prioritizing development of commercialization opportunities and market potential for both Tetra Bio-Pharma and Tetra Natural Health products. He will be overseeing all pre-launch activities such as Continuing Medical Education (CME), Medical Science Liaison (MSL) and Market Access/Reimbursement.

“Steeve has made significant contributions to Tetra since he joined the organization, and we look forward to his increased responsibilities on our senior management team,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “Steeve will play an increasingly critical role in ensuring that Tetra’s innovative pharmaceutical pipeline will be successfully commercialized globally.”

“With the legalization of cannabis in Canada, there are many new opportunities which have arisen globally for Tetra to build upon,” said Steeve Néron. “Having completed three months at Tetra, I am very excited by the innovative pipeline developed at Tetra and the boundless opportunities that await in growing and leveraging our brands in the marketplace.”

About Steeve Néron
Mr. Néron has more than 32 years’ experience in the pharmaceutical industry with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology where challenging the reimbursement landscape factored prominently in his role. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada, formerly Valeant.

Mr. Néron has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market leading pharmaceutical brands including Aerius™ (antihistamine), Altace™ (hypertension), Ezetrol™ (cholesterol), Eliquis™ (anti-coagulant), Lodalis™ (cholesterol) and Contrave™ (Obesity).

Tetra Bio-Pharma Completes Distribution of North Bud Farms Inc.
Tetra Bio-Pharma announced that it has completed the distribution (the “Distribution”) by way of dividend in kind of 15,500,000 common shares of North Bud Farms Inc. (each a “North Bud Share”) which were listed for trading on the Canadian Securities Exchange on September 20, 2018 under the symbol “NBUD” to the holders of record of outstanding common shares (each, a “Tetra Share”) of Tetra Bio-Pharma (the “Shareholders of Record”) as at September 7, 2018 (the “Dividend Record Date”). In accordance with the terms of the Distribution, Shareholders of Record received 0.1012 common share of North Bud Farms Inc. for every 1 Tetra Share outstanding as at the Dividend Record Date. Tetra Bio-Pharma determined that the estimated fair market value for the dividend-in-kind was set at a price of $0.25 per North Bud Share.

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
[email protected]
514-288-8500 ext. 226		 Stephanie Engel
[email protected]
416-425-9143 ext. 209

Tags: , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs $AERO $CBDS $CGRW $APH.ca $GBLX

#Cannabis industry says it needs more approved growers to meet Canadian demand $BOG.ca $NBUD.ca $MCOA

Posted by AGORACOM-JC at 10:09 AM on Monday, November 12th, 2018

  • More fully-licensed cannabis growers and cultivation space are needed to meet a voracious demand for legal marijuana, a spokesman for the industry said last week.
  • That means more licences for both producers and their grow areas need to be issued by Health Canada, said Allan Rewak, executive director of the Cannabis Council of Canada.
  • “Absolutely, we need more licensed producers, we need Health Canada to approve more production sites,” said Rewak, adding his group represents 85 per cent of the legal cultivation space in Canada.

Dean Pilling/Postmedia

More fully-licensed cannabis growers and cultivation space are needed to meet a voracious demand for legal marijuana, a spokesman for the industry said last week.

That means more licences for both producers and their grow areas need to be issued by Health Canada, said Allan Rewak, executive director of the Cannabis Council of Canada.

“Absolutely, we need more licensed producers, we need Health Canada to approve more production sites,” said Rewak, adding his group represents 85 per cent of the legal cultivation space in Canada.

“We’re talking to them every day.”

Private cannabis retailers in Alberta and across the country say the supply of product is often proving inadequate, with some insisting that shortage is preventing them from opening their stores a few weeks after the drug became recreationally legal on Oct. 17.

Alberta Gaming, Liquor and Cannabis, the provincial commission that distributes to private shops and sells pot online, echoes those sentiments.

On Friday, 72 of its 90 varieties of marijuana were listed as out of stock, while the number of total varieties had fallen by 100 from the day before.

Commission officials say they’ve canvassed all licensed producers in the country for more supply, but have been told there’s none to spare.

That bottleneck can be traced back to the federal government’s pace in approving producers’ ability to market their harvests, said AGLC spokeswoman Kaleigh Miller.

“There’s a lot of producers in the hopper waiting for a federal licence to sell,” said Miller.

Health Canada lists 132 producers as licensed to cultivate — nine in Alberta — though 78 of those have sales permits, which can take months to acquire.

Alberta has signed up 15 licensed producers to supply its market, though not all are making deliveries yet.

Those suppliers have reported inventory and shipped goods that should be enough to meet market requirements, said Health Canada spokesman Andre Gagnon.

“There will remain, in aggregate, more than enough supply of dried cannabis and cannabis oils to meet Canadian legal demand,” he said in a statement.

“The challenge will continue to be for licensed processors to work with distributors and retailers to process, package existing inventory and ship final products to meet consumer demand.”

In the past 16 months, he said, 89 companies were issued production licences and 46 granted sales permits, while growing space has expanded from two million to 13 million square feet.

Earlier this year, Postmedia reported that Health Canada was rejecting three licence applications for every one it approved, over concerns some of those requesting them had been involved in the black market.

Health Canada officials have said they’ve hired 300 additional staff to assess applications.

The Cannabis Council of Canada’s Rewak said he’s confident federal officials are working diligently to break the logjam.

“They’re working hard to migrate licences, no one is working against anybody else,” he said.

He also said the industry is working round the clock to meet demand, adding supply is making it to distributors and retailers.

“We’re not out of cannabis, it’s not like shelves are bare,” he said.

Millions of square feet of production capacity is being brought on line, which should help ease or erase supply gaps, said Rewak.

“In the weeks and months to come, it will normalize . . . we won’t see a completely rationalized market until the new year,” he said.

“We’ve got some great licensed producers at the final stages of approval.”

And he agrees with Health Canada that logistical hiccups, such as those in product packaging, are a factor in supply problems.

Included among those are difficulties in quickly affixing federal excise stamps to packaging, he said.

Another challenge has been the lack of data on cannabis demand, a realm shrouded in prohibition for 95 years, said Rewak.

“At the end of the day, there was no baseline to compare it to,” he said.

Overall, he said the system has worked reasonably well and expects it will eventually be proven a success.

Some estimates place the annual demand for cannabis at 800,000 kilograms in a market that could produce $6 billion in revenues.

Source: https://calgaryherald.com/cannabis/cannabis-business/cannabis-industry-says-it-needs-more-approved-growers-to-meet-canadian-demand

Tags: , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America, North Bud Farms Inc | Comments Off on #Cannabis industry says it needs more approved growers to meet Canadian demand $BOG.ca $NBUD.ca $MCOA

Dry Spell: Canada Runs Low on Legal #Marijuana Just Weeks After Its Approval $BOG.ca $NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 11:25 AM on Thursday, November 8th, 2018

  • Canada is running low on legal pot three weeks after the government approved the use of recreational marijuana, a shortage that is sending some frustrated consumers back to the black market
  • At least three provinces — Ontario, Quebec and New Brunswick — are facing a dearth of legal marijuana and two of them have seen outlets selling cannabis temporarily shut down for lack of supply.
  • “We need more weed!” said Trevor Tobin, who teamed up with his mother to open a marijuana retailer called High North in Labrador City, Newfoundland, a small mining town near the Quebec border.

MONTREAL — Canada is running low on legal pot three weeks after the government approved the use of recreational marijuana, a shortage that is sending some frustrated consumers back to the black market.

At least three provinces — Ontario, Quebec and New Brunswick — are facing a dearth of legal marijuana and two of them have seen outlets selling cannabis temporarily shut down for lack of supply.

“We need more weed!” said Trevor Tobin, who teamed up with his mother to open a marijuana retailer called High North in Labrador City, Newfoundland, a small mining town near the Quebec border. He said his suppliers did not grow enough plants and don’t have enough packaging equipment.

“It is the law of supply and demand,” Mr. Tobin said.

The shortage threatens to undermine a major aim of legalization: to tame an illegal marijuana trade estimated at about 5.3 billion Canadian dollars annually. Angry consumers across the country say they are returning to their illegal dealers. In Montreal, several pot smokers said their illegal dealers were taking advantage of the shortage by hawking home delivery services and lowering prices.

Retailers, consumers and the producers themselves say they are exasperated by the shortage, which is being blamed at least partly on the unexpected explosion of demand for government-approved marijuana and the slow pace at which the federal government has licensed cannabis producers.

Of the 132 producers approved by the government to supply marijuana to retailers, 78 have received sales licenses, according to Health Canada, the government department responsible for public health.

Breaking big stories requires support.

“We are building a new legal industry that wasn’t there three weeks ago, and we knew there would be problems,” said Mathieu Gaudreault, a spokesman for Quebec’s cannabis agency. He said demand had outstripped supply, while licensed producers had overestimated their capacity.

Bags of cannabis before being divided for sale at a dispensary in British Columbia.CreditAlana Paterson for The New York Times

“Producers can add more people to try and meet demand,” Mr. Gaudreault said. “But that won’t make the plants grow any faster.”

On Monday, New Brunswick became the latest province to confront a shortage as Cannabis NB, the provincial government agency charged with selling marijuana, temporarily closed half of its 20 stores, citing a production bottleneck. After about 20 percent of its first order was delivered, it said it was waiting for more marijuana deliveries to help plug the gap.

That followed the decision by Quebec’s provincial cannabis agency to shutter its 12 cannabis outlets three days a week until the supply can be replenished.

[Want more Canadian coverage in your inbox? Subscribe to our weekly Canada Letter newsletter.]

In Ontario, some frustrated pot smokers say they have returned to their illegal dealers. The Ontario Cannabis Store, the government retailer, received 150,000 orders in its first week of business and has been struggling to keep up with soaring demand. The problems have been exacerbated by a postal strike.

“The government is just feeding the black market and our customers are going there,” said Mr. Tobin, the shopkeeper. “We are called High North. But legal weed is in such short supply that no one is getting high on it.”

Mr. Tobin said that after opening the store on Oct. 17, the day of legalization, his entire marijuana supply sold out in four hours. Among the items flying off the shelves were a potent sativa strain that gives people a “creative and social buzz,” and pre-rolled joints, he said.

After waiting two weeks to get a new cannabis shipment, he said he had been forced to shutter the store for a week. He said he and his mother had invested about 100,000 Canadian dollars in the shop and were struggling to pay their bills.

His suppliers, who are licensed by the provincial government, had told him that they had underestimated demand. The store, which has now reopened, is trying to scrape by with the sales of paraphernalia like bongs and rolling papers. But Mr. Tobin said it was not enough for the business to be profitable.

Editors’ Picks

Live U.S. House Election Results

Live U.S. Senate Election Results

The Election in Pictures

His mother, Brenda Tobin, added that demand for government cannabis had surpassed expectations, in part because of the novelty but also because consumers were drawn by government marijuana being strictly regulated and free from contaminants found in some street marijuana.

Image

Clones from cuttings being dipped in a rooting powder to stimulate growth at Pure Sunfarms.CreditAlana Paterson for The New York Times

“People know what they are getting, and they like that,” she said.

André Gagnon, a spokesman for Health Canada, which is regulating the industry, said that Oct. 17 “marked the end of nearly a century of criminal prohibition of cannabis and the launch of an entirely new regulated industry in our country.”

“As with any new industry where there is considerable consumer demand, we expect there may be periods where inventories of some products run low or, in some cases, run out,” he said in a statement.

Given that marijuana had been illegal for so long, he added, the government didn’t have a reliable benchmark to know which products would be in high demand or to be able to estimate the demand level.

Producers, for their part, say that mastering a new industry invariably means a steep learning curve.

In the run-up to legalization, Aphria, a cannabis producer in Ontario, said it had been forced to dispose of 13,642 plants after a lack of qualified local labor hobbled its harvesting. Vic Neufeld, the company’s chief executive, predicted in October that there would be shortages and that the problem would improve when consumer demand was better understood.

“It’s like trying to merge a five-lane highway into a one-lane country road,“ he said. “It’s tough to get everything through the bottleneck on a timely basis.”

Mandesh Dosanjh, chief executive of Pure Sunfarms, a licensed cannabis producer based in British Columbia, said that shortages were not surprising given that producers were grappling with challenges such as mastering the growing of cannabis on a large scale, creating new supply chains across different provinces and allowing for rigorous and time-consuming inspections by Health Canada inspectors.

“It’s early days,” he said. “It’s hard to find know-how in an industry that was prohibited.”

Adam Greenblatt, a spokesman for Canopy Growth, one of the largest cannabis producers in the country, said the company was still building greenhouses in British Columbia, as it sought to accommodate a burgeoning market. Small things such as running out of the glue for the excise tax stamps required on every package of cannabis were causing some producers to have bottlenecks.

“Everyone is doing their best to meet demand,” he said. “Who would’ve thought that weed would be this popular?”

The Pure Sunfarms cultivation facility in VancouverCreditCreditAlana Paterson for The New York

Times
Source: https://www.nytimes.com/2018/11/07/world/canada/canada-marijuana-shortage.html

Tags: , , , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America, North Bud Farms Inc | Comments Off on Dry Spell: Canada Runs Low on Legal #Marijuana Just Weeks After Its Approval $BOG.ca $NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

#Weed Wins on Election Day. So What Comes Next? $BOG.ca $NBUD.ca $MCOA $APPB$AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:21 AM on Wednesday, November 7th, 2018

  • Michigan voted to legalize the recreational use of cannabis, while Utah and Missouri legalized it for medical use, according to projections made late Tuesday night. (A recreational measure in North Dakota failed, though medical cannabis remains legal there.)
  • They join 31 other states that have already gone the medical route, and nine others that have gone fully recreational
  • That’s a win for the citizens of these states—cannabis is far and away safer than alcohol and comes with a range of proven medical benefits, and still more that researchers are exploring

And so a few more dominoes fall. Michigan voted to legalize the recreational use of cannabis, while Utah and Missouri legalized it for medical use, according to projections made late Tuesday night. (A recreational measure in North Dakota failed, though medical cannabis remains legal there.) They join 31 other states that have already gone the medical route, and nine others that have gone fully recreational.

That’s a win for the citizens of these states—cannabis is far and away safer than alcohol and comes with a range of proven medical benefits, and still more that researchers are exploring. But it also may be a win for cannabis nationwide: The more states that legalize cannabis, the likelier it is that federal prohibition will topple soon.

“Momentum is gaining for change in Congress to allow states to determine their own marijuana policies,” says Morgan Fox, media relations director at the National Cannabis Industry Association. “Two thirds of the country wants marijuana to be legal, and politicians are ignoring that at their peril.”

This midterm election’s outcome is relevant to more than just the end game of dissolving the federal prohibition of cannabis. The momentum could also help the states that have already voted to legalize the drug but remain hamstrung by federal regulation. Over the summer, for instance, the Senate Appropriations Committee torpedoed an amendment that would have allowed banks to work with cannabis companies. This, of course, is a major headache for the industry: If a cultivator or distributor or dispensary can’t find a bank to work with, it’s kinda hard to do business.

States where marijuana is legal are also currently blocked from helping veterans gain better access to cannabis. In September, Congress stripped another amendment that would have allowed physicians affiliated with the Department of Veterans Affairs to recommend medical marijuana in states where it’s already legal.

So, the theory is that with more states voting to legalize, that attitude would trickle up to their representatives in Washington. And one particularly tall hurdle just fell. Republican Pete Sessions of Texas, the chairman of the House Rules Committee who’s been blocking votes on cannabis amendments, just lost to Democratic challenger Colin Allred. How serious is Allred about medical marijuana? It’s telling that he called Sessions out on the veterans amendment.

But then again, the cannabis momentum isn’t coming from politicians, but from the people. “One of the interesting political dynamics of cannabis legalization is that it’s happening in almost every state by ballot initiative,” says Ryan Stoa, author of the book Craft Weed: Family Farming and the Future of the Marijuana Industry. “Meaning, it’s not as if legislators are reading the tea leaves.”

Meaning, maybe we’re pinning too much hope on politicians to push for the federal reform their voters want. “For whatever reason, there still seems to be a lot of hesitation on behalf of politicians, even in the face of strong public support for legalization,” Stoa says.

It’s in a state’s best interest, though, to have cannabis legalized federally, because the economics of cannabis is nutso. Historically, California has provided perhaps three quarters of the domestically grown cannabis in the United States. That’s been over the black market, of course. But even though California has gone recreationally legal, that black market persists, both in-state (high taxes mean some patients skip the legal market) and across the country. Cultivators are “producing more supply than consumers are demanding in the state of California, which means a lot of that supply is going out of state on the black market,” says Stoa.

When a state goes legal, the cannabis sold in-state must be produced in-state (the feds don’t like interstate cannabis markets, for obvious reasons). But legalizing comes with severe growing pains. Small California growers, for instance, are buckling under the weight of new regulations meant to protect the environment and consumers. It’s mighty tempting, then, to skip selling to distributors (which in turn safety-test the product) and instead go black market and sell it all themselves out of state.

“The black market is thriving, and it’s going to continue to thrive,” says Swami Chaitanya, a (legal) grower in California’s legendary Mendocino County. “And the fact is that when it goes legal in those other states, then all of the persecution tends to drop down a level, until I imagine more black market will go to those states that are now legal.”

The fragmentation of the market could be especially acute in states that follow a similar, highly regulated legalization path as California, but that don’t have massive-scale local production of cannabis. Nevada had that problem, same with Colorado. But shortages would be less of a problem in the first place if cannabis were legal federally and producers could sell their products legitimately across state lines.

How Michigan, Utah, and Missouri settle into legal cannabis is to be seen, as is the pace with which Congress gets around to federal legalization. But a bit of bright news: we’ve got fresh faces. “With the new Congress,” says Chaitanya, “it’s almost a question of not so much, does it get legalized in most states, but are the congressional people elected going to be pro-cannabis?”

For the sake of their constituents, economies, prison systems, and the country in general, let’s hope so.

Source: https://www.wired.com/story/weed-wins-on-election-day-so-what-comes-next/?mbid=social_twitter

Tags: , , , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America, North Bud Farms Inc | Comments Off on #Weed Wins on Election Day. So What Comes Next? $BOG.ca $NBUD.ca $MCOA $APPB$AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Marijuana Company of America’s $MCOA #hempSMART (TM) Brand Announces Strategic Partnership with “As Seen on TV” to Launch Commercial Ad Campaign $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 8:28 AM on Tuesday, November 6th, 2018

15233 mcoa

  • Wholly owned subsidiary, hempSMART™, is launching a direct response television ad campaign in a strategic partnership with asseenontv.pro (ASONTV)
  • In early November 2018, ASONTV and hempSMART will release a television commercial campaign promoting the Company’s hempSMART Full Spectrum Pet Drops, formulated with 250mg of non-psychoactive hemp derived Cannabidiol (CBD) oil, on major cable networks in select regions across the United States.
  • 60 second TV ad campaign will run for 6 weeks from its starting date with a total of 300 different featured advertisement spots

Escondido, California–(November 6, 2018) – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company“) (OTC Pink: MCOA), an innovative hemp and cannabis corporation, is pleased to announce that its wholly owned subsidiary, hempSMART™, is launching a direct response television ad campaign in a strategic partnership with asseenontv.pro (ASONTV).

In early November 2018, ASONTV and hempSMART will release a television commercial campaign promoting the Company’s hempSMART Full Spectrum Pet Drops, formulated with 250mg of non-psychoactive hemp derived Cannabidiol (CBD) oil, on major cable networks in select regions across the United States. The 60 second TV ad campaign will run for 6 weeks from its starting date with a total of 300 different featured advertisement spots.

The ad campaign will promote hempSMART’s Pet Drops as an all-natural alternative for pet owners to traditional products in the market place. The Company anticipates that the increased attention gained from the commercial ad campaign could drive more customers to the other products featured under the hempSMART CBD product brand.

Donald Steinberg states, “As our hempSMART brand continues to grow, MCOA will continue to search for and utilize new partnerships that will uniquely market our incredible collection of all-natural CBD product formulations. We feel that our strategic partnership with ASONTV is an important milestone for the Company that will help promote our hempSMART Pet Drops to consumers across the country.”

To purchase hempSMART products, including the Full Spectrum Pet Drops, please visit: https://hempsmart.com/Shop.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s juridiction.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , ,
Posted in Marijuana Company of America | Comments Off on Marijuana Company of America’s $MCOA #hempSMART (TM) Brand Announces Strategic Partnership with “As Seen on TV” to Launch Commercial Ad Campaign $AERO $CBDS $CGRW $APH.ca $GBLX $ACG $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:57 AM on Thursday, November 1st, 2018

Logo tetrabiopharma rgb web

  • Announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.
  • This represents the first ever human clinical trial featuring a vaporized cannabinoid drug product 

OTTAWA, Nov. 01, 2018 — Tetra Bio-Pharma Inc. (“Tetra” or “TBP”) today announced that is has received a “No Objection Letter” (NOL) from the Therapeutic Drug Directorate at Health Canada to conduct a Phase 1 pharmacokinetic (PK) and safety study using a vaporized version of PPP001.

This study aims to determine the Pharmacokinetic and safety profile of PPP001 delivered as an inhaled vapour using the Mighty Medic (see previous July 16, 2018 News Release), thus providing patients with an alternative to the smoked version of PPP001 and allowing Tetra to develop PPP001 for healthier patients suffering from uncontrolled pain.   It is anticipated that this phase 1 data, combined with Tetra’s characterization of the composition of vapor, will provide the necessary evidence to advance the development of vaporized PPP001 into more chronic and non-life-threatening diseases, such as fibromyalgia. The study is expected to begin and end in Q4 2018.

“We are pleased to announce this critical Phase 1 trial focused on the PK and safety of our PPP001 pellet delivered by vaporization,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc. “Over the last 3 months we have analyzed the composition of the vapor.  This data combined with the results of this Phase 1 will provide the critical pharmacological information required by physicians to adequately guide future efficacy studies in patients who suffer from a chronic condition such as fibromyalgia where there are limited treatment options and there is a large unmet medical need.  It may also provide an alternative mode of delivery for those patients who prefer not to smoke.”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.  For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

 

Tags: , , , , ,
Posted in Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001 $AERO $CBDS $CGRW $APH.ca $GBLX

Tetra $TBP.ca Natural Health Signs Exclusive Agreement for the Distribution of their #Hemp Energy Drink in Canada and the USA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:55 AM on Thursday, November 1st, 2018

Logo tetrabiopharma rgb web

  • Announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink
  • In the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.

Tetra Natural Health Looking to Exploit Consumer Appetite for Hemp Based products

OTTAWA, Nov. 01, 2018 – Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed a major distribution agreement with Kombucha Baby Brewing Company and its partners for the exclusive distribution of its Hemp Energy Drink in the Provinces of British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario as well as California, Washington, Oregon and Hawaii.

The Hemp Energy Drink provides consumers with a product that contains fewer calories and more natural ingredients than existing energy drinks thus providing a welcome alternative to existing products in what is considered to be an extremely lucrative market.

“We are thrilled in having signed this agreement with Kombucha Baby and its distribution partners providing Tetra Natural Health with access to a significant number of retail outlets in both Canada and the USA,” stated Richard Giguere, CEO of Tetra Natural Health.

“We are very excited to be adding the Hemp Energy Drink to our portfolio of products that will be available to our existing and potential client base,” stated Dan McKenna, President and CEO of Kombucha Baby Brewing Company Inc. “Numerous Canadian and U.S. customers representing thousands of retail outlets have indicated a strong interest in carrying this unique Natural Health Product (NHP).”

About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including this trial, the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the success of various product launches including the one discussed in this release, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]

Media Contact
energi PR
Carol Levine
514-288-8500 ext. 226
[email protected]

Stephanie Engel
416-425-9143 ext. 209
[email protected]

Tags: , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra $TBP.ca Natural Health Signs Exclusive Agreement for the Distribution of their #Hemp Energy Drink in Canada and the USA $AERO $CBDS $CGRW $APH.ca $GBLX

Bougainville Ventures Inc. $BOG.ca Provides Corporate Update & Signs LOI with Oregon Hemp CBD Producer $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 2:06 PM on Monday, October 29th, 2018

681747 5720 copy 2

  • Signed a letter of intent to enter into a financing and profit-sharing agreement with Worm Castings Farms Inc., the sole owner of an Oregon state hemp production and processing license issued by the Oregon State Regulatory approval board

Bougainville Ventures Inc. has signed a letter of intent to enter into a financing and profit-sharing agreement with Worm Castings Farms Inc., the sole owner of an Oregon state hemp production and processing licence issued by the Oregon State Regulatory approval board. The material terms of the LOI are summarized below. LOI Terms

1. The parties shall enter into a funding and profit sharing agreement with both companies receiving dividends. The profit sharing percentages will be stipulated in the definitive agreement.

2. Bougainville will agree to issue to Worm Castings 600,000 shares of Bougainville Ventures Inc. for assets and goodwill of Worm Castings.

3. Bougainville will also agree to raise $350,000 USD to be used to fund Worm Castings’ business plan. The funds are expected to be provided on the following schedule:

a. $75,000 by November 7, 2018

b. $75,000 by November 30, 2018

c. $200,000 by December 31, 2018

4. Worm Castings will submit to Bougainville a complete list of assets to be included in the definitive agreement

About Worm Castings Farms Inc.

Worm Castings is a natural hemp company that currently has 10 acres of industrial hemp ready for harvest. They plant premium high quality cloned feminized hemp plants with 10-15% CBD and 0.3% THC resulting in maximized CBD oil content within each plant. In addition, they provide proven topsoil mix that improves plant growth by 20%. With this soil quality, they can expect to set standards in respective markets within the hemp industry.

CEO, Andy Jagpal Comments: “The objective of this project is to extract CBD oil from Hemp stock by providing the initial capital for the continued development of the 10 acre farmland and is a step in the right direction in diversifying our portfolio of companies in the cannabis infrastructure space .”

Oroville Campus Tier -3 Tenant Update

The Company also reports that it has recently become aware that Marijuana Company of America, Inc. (“MCOA”) has purportedly terminated its joint venture agreement with the Company dated March 16, 2017 (“JV Agreement”), and that it may have commenced legal action against the Company relating to various claims. The Company has not been served with a claim and has not receive a notice of default related to the JV agreement and will investigate this matter further. If subject to a claim, the Company intends to defend vigorously and to pursue all legal actions available to it. The Company notes that the JV Agreement relating to the acre of the 4.33 acre parcel of land located at Oroville Campus will continue for occupancy for its tenant.

Oroville Campus Tier -2 Tenant Update

The Company notes that the new I-502 Tier-2 licensee tenant and lease agreement relating to the 3.33 acre parcel of land in the Oroville Campus announced in the Company’s news release dated October 23, 2018 is not subject to the JV Agreement with MCOA and indeed resides on a separate parcel of land. Operations relating to such tenant are proceeding as previously announced.

About Bougainville Ventures, Inc.

Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost. Bougainville has 30,000 sqft in near production in Oroville, WA.

We seek Safe Harbor.

Tags: , , , , ,
Posted in All Recent Posts, Bougainville Ventures | Comments Off on Bougainville Ventures Inc. $BOG.ca Provides Corporate Update & Signs LOI with Oregon Hemp CBD Producer $CROP.ca $VP.ca NF.ca $MCOA

#Marijuana shortages abound in Canada in just second week of legalization $BOG.ca NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 10:54 AM on Monday, October 29th, 2018

  • The Canadian cannabis industry is still reeling from sky-high demand in the second week of legalization, with growers expressing frustration at the length of time it’s taking to get licensed as shelves sit empty.
  • “We’re biting our nails and I think our shareholders are biting their nails too,” said Anthony Durkacz, director at FSD Pharma Inc., an Ontario-based producer that received its cultivation licence a year ago and is still waiting for its sales licence. “We want to be supplying.”

People check out the sample counter at a cannabis store in Winnipeg, Man., on Oct. 17.Canadian Press/John Woods

Kristine Owram

The Canadian cannabis industry is still reeling from sky-high demand in the second week of legalization, with growers expressing frustration at the length of time it’s taking to get licensed as shelves sit empty.

“We’re biting our nails and I think our shareholders are biting their nails too,” said Anthony Durkacz, director at FSD Pharma Inc., an Ontario-based producer that received its cultivation licence a year ago and is still waiting for its sales licence. “We want to be supplying.”

Every province, not just Manitoba, is receiving less cannabis than originally requested

The process of getting a sales licence from Health Canada is onerous, according to Durkacz. After receiving a cultivation license, a grower must produce two full crops, send them off for testing, get its sales software audited, and then submit a completed application for the sales licence, which can take up to 341 days to process, he said.

“So even after you’ve done everything and done everything right you could be waiting up to a year to get the licence,” he said.

Customers lineup at a government cannabis store Oct. 19, in Montreal on the third day of the legal cannabis sales in Canada. Canadian Press/Ryan RemiorzCanada became the first major economy to legalize recreational cannabis on Oct. 17, taking the lead in a global market that’s expected to reach US$32 billion in consumer spending by 2022, according to Arcview Market Research and BDS Analytics. The euphoria that sent pot stocks soaring in the lead-up to legalization has faded, with the BI Canada Cannabis Competitive Peers index losing 26 per cent over seven sessions before rebounding on Thursday.

While some growers wait for their licences, others are struggling to keep up with demand. The government-run Ontario Cannabis Store received 100,000 orders in its first 24 hours. In Quebec, online and in-store orders totalled nearly 140,000 in the first week of legalization, and the provincial-owned retailer indicated Wednesday it may have to close some locations as producers couldn’t meet demand. Producers will have a “colossal” amount of work to do to ensure supply, the Societe Quebecoise du Cannabis said in a statement.

A man holds a bag of marijuana he bought in a cannabis store in Quebec City, on Oct. 17. Alice Chiche/AFP/Getty ImagesThe problem is that no one knew what the demand curve would look like after a century of prohibition, said Bruce Linton, chief executive officer of Canopy Growth Corp., which has secured more than a third of total Canadian supply committed to date.

Canopy shipped approximately 1 million orders of medical cannabis in its first four years of operations. It expects to ship more than 1 million units of recreational pot in the first four weeks after legalization, Linton said.

‘Just Outstanding’

“The response has been pretty unbelievable,” Linton said. “I don’t think everything will run out but you might not be able to get the identical stuff you got last time.”

He added that Canopy is sending out orders as fast as it can pack and ship them, but there have been delays in getting new product up on the provincial websites. It will start shipping out new products, including Tweed-brand gel caps and pre-rolled joints, over the next week and a half.

Bruce Linton (left), Canopy Growth CEO, in St. Johns, Newfoundland sells the first gram of legal pot at the Tweed store at the stroke of midnight Oct. 17. Julie Oliver/PostmediaInitial demand at Alberta Gaming, Liquor and Cannabis was “just outstanding,” said Chara Goodings, a spokeswoman for the government regulator that’s overseeing sales in the western province. “But it has created some struggles with our supply level.” Very few producers have been able to deliver what was agreed upon, she said.

Dried Bud

The situation is similar in Manitoba, where Winnipeg-based Delta 9 Cannabis Inc. only has dried bud on its store shelves as it has been unable to get any shipments of cannabis oils or gel caps, said spokesman Gary Symons. In the first seven days, Delta 9 saw close to 9,600 transactions totalling $736,124 in revenues. The company is now selling about $50,000 worth of product a day.

“Every province, not just Manitoba, is receiving less cannabis than originally requested,” Susan Harrison, spokeswoman for Manitoba Liquor & Lotteries, said in an email.

Aphria Inc. CEO Vic Neufeld predicted the supply shortages on the company’s earnings call five days before legalization. Citing supply-chain issues, labor shortages and delays in getting licences and excise stamps from the government, Neufeld said Aphria would be unable to meet demand in the first two to three months after legalization. The company was forced to destroy almost 14,000 plants worth $979,000 in the last quarter due to a lack of qualified greenhouse workers.

Extra Staff

There are currently 132 licensed producers in Canada and “many more are in the queue,” said Canadian Health Minister Ginette Petitpas Taylor. Health Canada has hired 300 additional staff to evaluate applications, she said. But the process, which includes background checks, is time-consuming and it’s important to not cut corners, she said.

“There’s not a mass shortage of cannabis around the country right now,” only certain strains that have sold out, Petitpas Taylor said. “We really have all hands on deck, we want to do what we can, but in no way am I going to compromise this new regime.”

The challenge for the government is balancing public safety with a desire to eradicate the illicit market, said Deepak Anand, vice president of business development and government relations at Cannabis Compliance Inc., a consulting firm for pot companies which is currently working on “hundreds” of licensing applications.

“Health Canada’s trying to balance quality and public safety with the need for getting more product on so that they can eliminate the black market,” Anand said. “Sometimes these goals conflict and compete with each other.”

The only near-term solution to the supply shortage, according to Durkacz at FSD Pharma, is to allow retailers to sell product sourced from the black market.

“You would instantaneously have a supply-demand balance and then you could try to convert people from the black market to the legalized market,” he said. “That’s probably the only way to solve this in the short term.”

Source: https://business.financialpost.com/cannabis/cannabis-business/marijuana-shortages-abound-in-canada-amid-licensing-rigmarole

Tags: , , , , ,
Posted in All Recent Posts, Bougainville Ventures, Marijuana Company of America, North Bud Farms Inc | Comments Off on #Marijuana shortages abound in Canada in just second week of legalization $BOG.ca NBUD.ca $MCOA $ACG.ca $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, October 24th, 2018

Logo tetrabiopharma rgb web

  • Announced the appointment of Richard Giguère to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.
  • Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market

ORLEANS, Ontario, Oct. 24, 2018 РTetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced the appointment of Richard Gigu̬re to the position of Chief Executive Officer of Tetra Natural Health Inc. a newly created, wholly owned subsidiary of Tetra Bio-Pharma Inc.

Mr. Giguère has more than 20 years’ experience in national sales and marketing in the pharmaceutical industry. During his career, he has held numerous business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for several pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships. Over the past 10 years, he served as a member of the Board of Directors of the companies for which he worked.

“Richard has demonstrated his ability as a company builder which will prove crucial in his role as Chief Executive Officer of Tetra Natural Health,” stated Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma Inc.  “He has begun preparing Tetra Natural Health as a wholly owned subsidiary of Tetra Bio-Pharma with the intentions of creating a market leader in the wellness sector of the cannabis market.”

“I am honored by this appointment as well by the confidence that Tetra Bio-Pharma has shown in me,” said Richard Giguère, CEO of Tetra Natural Health Inc. “As the CEO of Tetra Natural Health, I am excited and deeply committed to lead the operations of Tetra Natural Health with my colleagues through the next stages of development and success. Tetra has a sound business model, and there are several significant opportunities for Tetra Natural Health to grow and commercialize innovative natural health products. I am committed to exploiting the development of this huge potential market in the natural health sector.”

About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.
Robert Bechard
Executive Vice-President Corporate Development and Licensing
514-817-2514
[email protected]
Media Contact
Energi PR
Carol Levine Stephanie Engel
514-288-8500 ext. 226 416-425-9143 ext. 209
[email protected] [email protected]

Tags: , , , , , ,
Posted in All Recent Posts, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »